PATIENTS WITH TYPE 1 DIABETES PLANNING AND DURING PREGNANCY
- 27 year-old female.
- Type 1 diabetes for 14 years
- MDI – long acting in the morning and rapid acting before each meal and snack
- HbA1c: 7.5% (58mmol/mol)
The patient would like to start planning pregnancy but has never achieved a HbA1c of 6.5% (47mmol/mol).
The patient’s goal is to achieve and maintain HbA1c of 6.5% (47mmol/mol), prior to conceiving - and throughout her pregnancy - to avoid complications.
Pregnant women and women planning to conceive may be good candidates for CSII diabetes treatment1.
1Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F, Vitacolonna E, Dodesini AR, Tonutti L, Lapolla A, Di Benedetto A, Torlone E; Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab. 2011 Nov;37(5):426-31.
22011 Guideline for Management of PostMeal Glucose in Diabetes. © International Diabetes Federation, ISBN 2-930229-81-0 www.idf.org.
3All therapy adjustments should be based on measurements obtained using a home blood glucose monitor and not based on the value displayed by the pump.
4Ref: Corrigan N, Brazil DP, McAuliffe F. Fetal cardiac effects of maternal hyperglycemia during pregnancy. Birth Defects Res A Clin Mol Teratol. 2009 Jun;85(6):523-30.
PATIENT TYPE 1 ADULT
Considerations for adult type 1 patients with diabetes
SENSOR AUGMENTED PUMP THERAPY (SAP)
Incorporating Continuous Glucose Monitoring to reduce HbA1c and improved glycaemic control.
INSULIN PUMP THERAPY (CSII)
Introducing patients to new technologies and clinical practices